SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JMarcus who wrote (7441)1/7/2000 10:46:00 PM
From: chirodoc  Read Replies (2) of 9719
 
investor relations at avxt told me a few interesting things:
1. they will not give out price for vaccine--that is confidential at this point. margins?
2. they said that margins would be the same as most pharmas = 65-95% that answers the criticism that cost could be prohibitive for wide distribution.
3. they will rent space in australia soon in another pharma house or lab--purchase will come later.
4. they have approval in australia, netherlands, japan, germany but NOT new zealand.
5. the PII they are doing in u.s. has 400 patients and thus could satisfy FDA for full approval--probably will take till 2002-2003.

after talking to him, i bought another 1,000 shares.

curtis
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News